tenofovir has been researched along with Disease Models, Animal in 60 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.67) | 18.2507 |
| 2000's | 22 (36.67) | 29.6817 |
| 2010's | 30 (50.00) | 24.3611 |
| 2020's | 7 (11.67) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Huang, X; Kallakury, BV; Kim, YW; Korolowicz, KE; Lee, KP; Li, B; Menne, S; Park, S; Suresh, M; Yon, C | 1 |
| Achim, CL; Calcutt, NA; Carson, A; Ellis, RJ; Fields, JA; Frizzi, K; Han, MM; Lindsay, C; Murphy, A; Sambhwani, S; Soontornniyomkij, B; Swinton, MK | 1 |
| Chen, X; Cheng, J; Feng, S; Han, K; Han, M; Liang, P; Liu, S; Lu, H; Wang, Y; Yuan, X; Zhao, J; Zhou, L | 1 |
| Caldwell, A; Cuppone, AM; Dereuddre-Bosquet, N; Desjardins, D; Frank, B; Grand, RL; Gwozdz, G; Hijazi, K; Iannelli, F; Kelly, C; Mukhopadya, I; Pozzi, G; Santoro, F; Scala, C; Smith, KA | 1 |
| Abboussi, O; Daniels, WMU; Mabandla, MV; Simola, N; Zulu, SS | 1 |
| Afolayan, S; Agumah, R; Akang, E; Akanmu, AS; Dosumu, O | 1 |
| Anderson, DM; Beck, IA; Frenkel, LM; Hu, SL; Joy, JP; Kuller, L; Montefiori, DC; Mulvania, TM; Tsai, CC | 1 |
| Corciulo, C; Cronstein, B; Feig, JL; Liu, H; Mediero, A; Perez-Aso, M; Picard, L; Wilder, T; Zhang, J | 1 |
| Apetrei, C; Dunsmore, T; Haret-Richter, G; Pandrea, I; Policicchio, BB; Ribeiro, RM; Sette, P; Xu, C | 1 |
| Babusis, D; Callebaut, C; Cong, ME; Deyounks, F; Dinh, C; García-Lerma, JG; Heneine, W; Holder, A; Johnson, R; Khalil, G; Lipscomb, J; Massud, I; McCallister, S; Nishiura, K; Pan, Y; Park, Y; Rooney, JF; Ruone, S | 1 |
| Herold, BC; Jandl, T; Kiser, PF; Nagaraja, U; Nixon, B; Taneva, E; Teller, RS; Wang, Y | 1 |
| Akkina, R; Kashuba, ADM; LeCureux, J; Remling-Mulder, L; Sykes, C; Veselinovic, M; Yang, KH | 1 |
| Alt, C; Shankar, GN | 1 |
| Chandra, N; Doncel, GF; Fichorova, RN; Mendonca, K; Murray, R; Yamamoto, HS | 1 |
| Durantel, D; Zoulim, F | 1 |
| Cameron, D; Dias, N; Dreier, P; Holding, J; Holt, JD; Muntendam, A; Nuttall, J; Oostebring, F; Rohan, L | 1 |
| Anderson, PL; Bushman, LR; Chuong, D; Dobard, CW; Garcia-Lerma, JG; Hanson, D; Heneine, W; McGowan, I; Pau, CP; Rohan, L; Sharma, S; Taylor, A; Wang, L | 1 |
| Destache, CJ; Fan, W; Kang, G; Li, Q; Li, Y; Lu, W; Tso, FY; Wood, C; Yuan, Z | 1 |
| Cong, ME; Dobard, CW; Garcia-Lerma, JG; Hanson, DL; Heneine, W; Holder, A; Makarova, N; Novembre, FJ; Pau, CP; Sharma, S; West, R | 1 |
| Kosinska, AD; Liu, J; Lu, M; Roggendorf, M | 1 |
| Anderson, PL; García-Lerma, JG; Heneine, W | 1 |
| Menne, S; Paulsen, D; Ruebsamen-Schaeff, H; Tennant, BC; Weber, O | 1 |
| Gavegnano, C; Haile, WB; Jiang, Y; Schinazi, RF; Tao, S; Tyor, WR | 1 |
| Bruck, P; Date, AA; Destache, CJ; Fletcher, CV; Kang, G; Li, Q; Lu, W; Mandal, S; Pham, R; Rezich, M; Shibata, A; Vivekanandan, R; Yuan, Z; Zhou, Y | 1 |
| Akula, SM; Artola, RT; Barone Gibbs, B; Bielke, LR; Bironaitė, D; Bogomolovas, J; Bukelskienė, V; Burke, LE; Chen, B; Chen, D; Chen, WJ; Cook, FJ; Cook, PP; Cotutiu, P; Cui, Y; Davis, KK; Dumitras, DE; El-Sayed, MA; Grabauskienė, V; Gretz, N; Gupta, R; Hargis, BM; Heck, C; Hernandez-Velasco, X; Huang, W; Huete-Ortega, M; Jakicic, JM; Jian, J; Jiang, K; Jiang, M; Jiang, Q; Jin, T; Kiuchi, M; Kovacs, SJ; Labeit, D; Labeit, S; Lang, W; Lang, XY; Latorre, JD; Li, HF; Li, J; Li, YQ; Lin, H; Lin, X; Liu, BT; Liu, M; Longworth, J; Lu, JB; Luo, C; Mahmoud, MA; Marx, A; Menconi, A; Mihos, CG; Muresan, D; Notter, RH; Pant, B; Petrisor, FM; Podkopajev, A; Popp, RA; Portzer, LA; Pradhan, S; Qian, G; Ranjit, M; Regmi, T; Rinkūnaitė, I; Rogers, RJ; Rotar, IC; Sakurai, H; Santana, O; Schwan, AL; Shi, XM; Shkoor, MG; Šimoliūnas, E; Smalinskaitė, L; Stamatian, F; Stang, AT; Tellez, G; Vaidyanathan, S; Vicente, JL; Walker, LR; Walther, FJ; Wan, Y; Wang, H; Wang, X; Wang, Z; Weis, CA; Wen, Z; Wolfenden, AD; Wolfenden, RE; Wright, PC; Wu, D; Xing, H; Xiong, X; Yang, H; Yang, Y; Yu, Q; Yue, D; Zang, Q; Zhang, L; Zhao, B; Zheng, Y; Zhou, L; Zhou, M; Zhuge, F | 1 |
| Abel, K; Bischofberger, N; Brignolo, LL; Cihlar, T; Durand-Gasselin, L; Jerome, C; Kearney, BP; Marthas, ML; Moore, J; Ray, AS; Reiser, H; Spinner, A; Van Rompay, KK | 1 |
| Butler, SD; Cote, PJ; George, AL; Gerin, JL; Menne, S; Tennant, BC; Tochkov, IA; Xiong, S; Zhu, Y | 1 |
| Brenchley, J; Buckler-White, A; Igarashi, T; Kubo, M; Lafont, B; Lee, W; Martin, MA; Nishimura, Y; Shingai, M | 1 |
| Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S | 1 |
| Cheshenko, N; Fakioglu, E; Herold, BC; Keller, MJ; Mesquita, PM; Wilson, SS | 1 |
| Aung, W; Cong, ME; Dobard, C; Garcia-Lerma, JG; Heneine, W; Mitchell, J; Sharma, S; Youngpairoj, AS | 1 |
| Appella, E; Denton, PW; Estes, JD; Fleming, E; Gallay, P; Garcia, JV; Kay, MS; Krisko, JF; Kwak, YT; Lu, M; Martinez-Torres, F; Othieno, F; Payne, DA; Powell, DA; Wahl, A; Welch, BD; Zein, S; Zou, W | 1 |
| Baum, MM; Butkyavichene, I; Clark, MR; Friend, DR; Gilman, J; Kennedy, S; Kopin, E; Malone, AM; Moss, JA; Motamedi, M; Nguyen, C; Smith, TJ; Vincent, KL | 1 |
| Heneine, W; Kashuba, A | 1 |
| Abel, K; Canfield, DR; Forthal, DN; Geng, Y; Heneine, W; Jayashankar, K; Johnson, JA; LaBranche, CC; Landucci, G; Lipscomb, J; Montefiori, D; Tarara, RP; Trott, KA; Van Rompay, KK | 1 |
| Murakami, T; Nakasone, T; Yamamoto, N | 1 |
| Melchjorsen, J; Paludan, SR; Reinert, LS; Søgaard, OS; Tolstrup, M; Vibholm, L; Østergaard, L | 1 |
| Grulich, AE; Poynten, IM; Zablotska, I | 1 |
| Chateau, M; Garcia, JV; Swanson, MD | 1 |
| Budeus, B; Cao, L; Chen, X; Hoffmann, D; Lu, M; Qin, B; Rayner, S; Wang, Y; Wu, C; Zhang, X | 1 |
| Bischofberger, N; Lawson, JR; Marthas, ML; Schmidt, KA; Singh, R; Van Rompay, KK | 1 |
| Chen, ZW; Du, GZ; Huang, D; Letvin, NL; Miller, MD; Qiu, L; Sehgal, P; Shen, L; Shen, Y | 1 |
| De Clercq, E | 1 |
| Bullock, B; Carruth, LM; Clements, JE; Gama, L; Li, M; Mankowski, JL; Zink, MC | 1 |
| Grant, RM; Wainberg, MA | 1 |
| Adams, DR; Bashirian, S; Butera, S; Folks, TM; Greenberg, AE; Hudgens, MG; Jackson, E; Janssen, R; Johnson, J; Kim, C; Monsour, M; Otten, RA; Paxton, L; Ramos, A; Rendon, A; Soriano, V; Subbarao, S | 1 |
| Delwart, E; Heneine, W; Johnson, JA; Rompay, KK | 1 |
| Bischofberger, N; Blackwood, EJ; Heneine, W; Johnson, JA; Lipscomb, J; Marthas, ML; Matthews, TB; North, TW; Pedersen, NC; Singh, RP; Van Rompay, KK | 1 |
| Dandekar, S; Sankaran, S; Verhoeven, D | 1 |
| Adams, D; Butera, S; Folks, T; Kim, C; Monsour, M; Otten, RA; Ramos, A; Subbarao, S | 1 |
| Clayton, MM; Feitelson, MA; Schinazi, RF; Sun, B | 1 |
| Shacklett, BL | 1 |
| Denton, PW; Estes, JD; Garcia, JV; Haase, AT; Othieno, FA; Payne, D; Powell, DA; Sun, Z; Wege, AK; Wei, BL | 1 |
| Black, RJ | 1 |
| Adany, I; Bischofberger, N; Buch, S; Foresman, L; Li, Z; Lifson, JD; Lopez, GJ; Narayan, O; Page, A; Smith, MS; Tsay, J; Wang, C; Wodarz, D | 1 |
| Beck, TW; Bischofberger, N; Emau, P; Follis, KE; Morton, WR; Sun, JC; Tran, CA; Tsai, CC | 1 |
| Bischofberger, N; Buch, S; Foresman, L; Kumar, A; Lifson, JD; Narayan, O | 1 |
| Bischofberger, N; Dittmer, U; Heeney, J; Hunsmann, G; Lorenzen, D; Ràcz, P; Spring, M; Stahl-Hennig, C; Stolte, N; Tenner-Ràcz, K | 1 |
9 review(s) available for tenofovir and Disease Models, Animal
| Article | Year |
|---|---|
Antiviral therapies and prospects for a cure of chronic hepatitis B.
Topics: Animals; Antiviral Agents; Disease Management; Disease Models, Animal; Drug Therapy, Combination; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Interferon-alpha; Mice; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2015 |
The Woodchuck, a Nonprimate Model for Immunopathogenesis and Therapeutic Immunomodulation in Chronic Hepatitis B Virus Infection.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Guanine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Immunization Schedule; Marmota; T-Lymphocytes; Tenofovir; Vaccines, DNA; Virus Replication | 2015 |
Nondaily preexposure prophylaxis for HIV prevention.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV Infections; Humans; Macaca; Male; Pre-Exposure Prophylaxis; Tenofovir | 2016 |
Topics: Absorptiometry, Photon; Adult; Air Pollutants; Alkynes; Alleles; Animals; Anthracenes; Anthraquinones; Anti-HIV Agents; Benzoxazines; Black or African American; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium, Dietary; Capsid Proteins; Cardiomyopathy, Dilated; Cardiovascular Diseases; CD4 Lymphocyte Count; Cholesterol; Collagen Type I; Cyclopropanes; Darunavir; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Emtricitabine; Epitopes; Female; Femur Neck; Gene Expression Profiling; Genetic Predisposition to Disease; Hepatitis, Viral, Animal; Hip Joint; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunization; Inflammation Mediators; Lipoproteins, LDL; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred BALB C; Nitrates; Osteocalcin; Oxidation-Reduction; Parathyroid Hormone; Parvovirus B19, Human; Peptides; Phenotype; Pilot Projects; Polymorphism, Single Nucleotide; Raltegravir Potassium; Ritonavir; RNA, Viral; Sodium Chloride; Tenofovir; Transcriptome; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms; Vaccines; Vascular Endothelial Growth Factor A; Vitamin D; Young Adult | 2016 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Diseases; Child; Child, Preschool; Congenital Abnormalities; Disease Models, Animal; Drug Resistance, Viral; Female; Health Services Accessibility; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Macaca; Mitochondria; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Zidovudine | 2009 |
HIV prevention by oral preexposure prophylaxis.
Topics: Adenine; Administration, Oral; Animals; Anti-Retroviral Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Seronegativity; Humans; Male; Mucous Membrane; Organophosphonates; Protein Binding; Rectum; Tenofovir; Vagina; Virus Replication | 2012 |
Considerations regarding antiretroviral chemoprophylaxis in MSM.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Chemoprevention; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Leukocytes, Mononuclear; Male; Medication Adherence; Organophosphonates; Plasma; Tenofovir; Treatment Outcome | 2012 |
Potential of acyclic nucleoside phosphonates in the treatment of DNA virus and retrovirus infections.
Topics: Adenine; Animals; Antiviral Agents; Cidofovir; Cytosine; Disease Models, Animal; DNA Virus Infections; Drug Resistance, Viral; Humans; Organophosphonates; Organophosphorus Compounds; Retroviridae Infections; Tenofovir | 2003 |
Animal studies of prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Administration Schedule; Interferon-alpha; Lentivirus Infections; Organophosphonates; Organophosphorus Compounds; Retroviridae Infections; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 1997 |
1 trial(s) available for tenofovir and Disease Models, Animal
51 other study(ies) available for tenofovir and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Combination Treatment with the Vimentin-Targeting Antibody hzVSF and Tenofovir Suppresses Woodchuck Hepatitis Virus Infection in Woodchucks.
Topics: Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; Disease Models, Animal; Drug Therapy, Combination; Endocytosis; Hep G2 Cells; Hepatitis B; Hepatitis B Virus, Woodchuck; Host-Pathogen Interactions; Humans; Liver; Marmota; Tenofovir; Vimentin; Viral Load; Virus Internalization; Virus Replication | 2021 |
Tenofovir disoproxil fumarate induces peripheral neuropathy and alters inflammation and mitochondrial biogenesis in the brains of mice.
Topics: Animals; Anti-HIV Agents; Brain; Cell Line; Disease Models, Animal; Gene Expression; Humans; Inflammation; Mice; Mice, Transgenic; Mitochondria; Neurons; Organelle Biogenesis; Peripheral Nervous System Diseases; Signal Transduction; Tenofovir | 2019 |
TAF and TDF attenuate liver fibrosis through NS5ATP9, TGFβ1/Smad3, and NF-κB/NLRP3 inflammasome signaling pathways.
Topics: Adenine; Alanine; Animals; Antiviral Agents; Carbon Tetrachloride; Disease Models, Animal; DNA-Binding Proteins; Liver Cirrhosis, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Smad3 Protein; Tenofovir; Transforming Growth Factor beta | 2020 |
Topics: Administration, Intravaginal; Animals; Biological Transport; Cell Line, Tumor; Darunavir; Disease Models, Animal; Drug Compounding; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Macaca fascicularis; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Tenofovir; Tissue Distribution; Up-Regulation; Vagina | 2020 |
Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice.
Topics: Administration, Oral; AIDS Dementia Complex; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Anti-HIV Agents; Aspartic Acid Endopeptidases; Brain; Cognitive Dysfunction; Disease Models, Animal; Female; Hippocampus; HIV Infections; HIV-1; Learning Disabilities; Lipid Peroxidation; Maze Learning; Memory; Mice; Mice, Inbred BALB C; Nevirapine; Tenofovir | 2020 |
Modeling cerebellar limb dysmetria and impaired spatial memory in rats using lamivudine: A preliminary study.
Topics: Alkynes; Animals; Benzoxazines; Cerebellar Ataxia; Cyclopropanes; Disease Models, Animal; Lamivudine; Male; Maze Learning; Rats; Rats, Wistar; Spatial Memory; Tenofovir | 2020 |
Immunization by exposure to live virus (SIVmne/HIV-2287) during antiretroviral drug prophylaxis may reduce risk of subsequent viral challenge.
Topics: Animals; Anti-Retroviral Agents; Disease Models, Animal; Female; HIV Infections; HIV-2; Humans; Immunization; Macaca nemestrina; Pre-Exposure Prophylaxis; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2021 |
The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.
Topics: Adenosine; Adenosine Triphosphate; Animals; Antiviral Agents; Connexins; Disease Models, Animal; Dose-Response Relationship, Drug; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Skin; Skin Diseases; Tenofovir | 2017 |
Emergence of resistance mutations in simian immunodeficiency virus (SIV)-infected rhesus macaques receiving non-suppressive antiretroviral therapy (ART).
Topics: Animals; Anti-Retroviral Agents; Disease Models, Animal; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Genes, Viral; Humans; Integrases; Macaca mulatta; Mutation; Raltegravir Potassium; RNA-Directed DNA Polymerase; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Viral Load | 2018 |
Efficacy of Oral Tenofovir Alafenamide/Emtricitabine Combination or Single-Agent Tenofovir Alafenamide Against Vaginal Simian Human Immunodeficiency Virus Infection in Macaques.
Topics: Adenine; Alanine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Disease Transmission, Infectious; Emtricitabine; Female; HIV; HIV Infections; Macaca; Pre-Exposure Prophylaxis; Simian Immunodeficiency Virus; Tenofovir; Treatment Outcome; Vagina | 2019 |
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety.
Topics: Adenine; Administration, Intravaginal; Animals; Antiviral Agents; Contraceptive Devices, Female; Disease Models, Animal; Drug Administration Schedule; Female; Herpes Genitalis; Herpesvirus 2, Human; Humans; Mice; Mice, Inbred BALB C; Organophosphonates; Survival Analysis; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2014 |
HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.
Topics: Adenine; Animals; Anti-HIV Agents; Cyclohexanes; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Maraviroc; Mice; Mucous Membrane; Organophosphonates; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Virus Internalization | 2014 |
Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.
Topics: Acrylic Resins; Acyclovir; Adenine; Animals; Anti-Infective Agents; Chlorocebus aethiops; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Female; Herpes Genitalis; Herpesvirus 2, Human; Mice, Inbred BALB C; Organophosphonates; Poloxamer; Rabbits; Rats, Sprague-Dawley; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Vero Cells | 2014 |
A quantitative multiplex nuclease protection assay reveals immunotoxicity gene expression profiles in the rabbit model for vaginal drug safety evaluation.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation, Preclinical; Evaluation Studies as Topic; Female; Host-Pathogen Interactions; Immunohistochemistry; Inflammation; Interleukin-1beta; Interleukin-8; Mucous Membrane; Nonoxynol; Nuclease Protection Assays; Oligopeptides; Organophosphonates; Rabbits; Tenofovir; Toll-Like Receptor 4; Transcriptome; Vagina | 2015 |
The sheep as a model of preclinical safety and pharmacokinetic evaluations of candidate microbicides.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Contraceptive Devices, Female; Disease Models, Animal; Drug Carriers; Female; HIV Infections; Pyrimidines; Sheep; Tenofovir; Vagina; Vaginal Creams, Foams, and Jellies | 2015 |
Protection Against Rectal Chimeric Simian/Human Immunodeficiency Virus Transmission in Macaques by Rectal-Specific Gel Formulations of Maraviroc and Tenofovir.
Topics: Administration, Topical; Animals; Anti-HIV Agents; Cross-Over Studies; Cyclohexanes; Disease Models, Animal; Disease Transmission, Infectious; Gels; Macaca; Maraviroc; Placebos; Simian Acquired Immunodeficiency Syndrome; Tenofovir; Treatment Outcome; Triazoles | 2015 |
Early Initiation of Antiretroviral Therapy Can Functionally Control Productive HIV-1 Infection in Humanized-BLT Mice.
Topics: Adenine; Animals; Anti-HIV Agents; Antigens, CD34; Bone Marrow; CD8-Positive T-Lymphocytes; Disease Models, Animal; Disease Progression; DNA, Viral; Gene Dosage; HIV Infections; HIV-1; Humans; Liver; Mice; Mice, Inbred NOD; Mice, Transgenic; Organophosphonates; Pilot Projects; RNA, Viral; Spleen; Tenofovir; Thymus Gland; Viral Load; Virus Replication | 2015 |
Efficacy of topical tenofovir against transmission of a tenofovir-resistant SHIV in macaques.
Topics: Administration, Intravaginal; Animals; Disease Models, Animal; Drug Resistance, Viral; Female; Gels; HIV; HIV Infections; Humans; Macaca radiata; Pre-Exposure Prophylaxis; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Vagina | 2015 |
AIC649 Induces a Bi-Phasic Treatment Response in the Woodchuck Model of Chronic Hepatitis B.
Topics: Animals; Antiviral Agents; Biological Therapy; Biomarkers; Dendritic Cells; Disease Models, Animal; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Immunity, Cellular; Interferon-alpha; Interferon-gamma; Killer Cells, Natural; Lymphocyte Activation; Marmota; Mice; Mice, Inbred BALB C; Mice, Transgenic; Parapoxvirus; T-Lymphocytes; Tenofovir; Tumor Necrosis Factor-alpha; Vaccines, Inactivated; Virus Replication | 2015 |
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Topics: Animals; Antiviral Agents; Astrocytes; Blood-Brain Barrier; Disease Models, Animal; Encephalitis, Viral; Gliosis; HIV Infections; HIV-1; Humans; Janus Kinase Inhibitors; Macrophages; Male; Mice; Monocytes; Nitriles; Pyrazoles; Pyrimidines; Tenofovir; Virus Replication | 2016 |
Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Topics: Administration, Intravaginal; Animals; Anti-HIV Agents; Disease Models, Animal; Emulsifying Agents; Female; HIV Infections; HIV-1; Humans; Lactic Acid; Mice; Mice, Transgenic; Nanoparticles; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Primary Prevention; RNA, Viral; Temperature; Tenofovir; Time Factors; Vagina; Vaginal Creams, Foams, and Jellies; Viral Load | 2016 |
Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects.
Topics: Adenine; Age Factors; Animals; Anti-HIV Agents; Disease Models, Animal; Female; HIV Infections; HIV-1; Humans; Macaca mulatta; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Treatment Outcome | 2008 |
Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection.
Topics: Adenine; Animals; Antigens, Viral; Antiviral Agents; Deoxycytidine; Disease Models, Animal; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B Virus, Woodchuck; Hepatitis B, Chronic; Humans; Lamivudine; Liver; Marmota; Organophosphonates; RNA, Viral; Rodent Diseases; Tenofovir; Virus Replication | 2008 |
Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Topics: Adenine; Amino Acid Sequence; Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Disease Models, Animal; Drug Administration Schedule; HIV Antibodies; HIV Infections; Humans; Injections; Macaca mulatta; Molecular Sequence Data; Organophosphonates; Sequence Alignment; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Viremia; Virus Replication | 2009 |
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-Infective Agents; Antiviral Agents; Biomarkers; Disease Models, Animal; Disease Susceptibility; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; Mice; Mice, Inbred BALB C; Naphthalenesulfonates; Nonoxynol; Organophosphonates; Polymers; Predictive Value of Tests; Risk Assessment; Tenofovir | 2009 |
Findings in humanized-mouse model suggest benefit of further studies in HIV pre-exposure prophylaxis.
Topics: Adenine; Animals; Anti-HIV Agents; Bone Marrow Transplantation; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Drug Combinations; Emtricitabine; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Antibodies; HIV Infections; Humans; Infection Control; Liver Transplantation; Mice; Occupational Exposure; Organophosphonates; Organophosphorus Compounds; Tenofovir; Thymus Gland; Transplantation Chimera | 2010 |
Generation and mucosal transmissibility of emtricitabine- and tenofovir-resistant SHIV162P3 mutants in macaques.
Topics: Adenine; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Resistance, Viral; Emtricitabine; HIV; Humans; Macaca; Mutation; Organophosphonates; Recombination, Genetic; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Virus Cultivation | 2011 |
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Topics: Adenine; Administration, Topical; Animals; Base Sequence; CD4-Positive T-Lymphocytes; Chimera; Disease Models, Animal; DNA Primers; Drug Evaluation, Preclinical; Female; HIV Infections; Humans; Mice; Organophosphonates; Receptors, CCR5; Reverse Transcriptase Inhibitors; Tenofovir; Vagina | 2011 |
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring.
Topics: Acyclovir; Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Antiviral Agents; Delayed-Action Preparations; Disease Models, Animal; Drug Combinations; Drug Delivery Systems; Equipment Design; Female; Herpes Genitalis; Herpesvirus 2, Human; HIV Infections; HIV-1; Humans; Organophosphonates; Rabbits; Sexually Transmitted Diseases, Viral; Tenofovir; Treatment Outcome | 2012 |
Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal.
Topics: Adenine; Alleles; Animals; Antibodies, Viral; Antibody Formation; Antiviral Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Disease Models, Animal; Genes, MHC Class I; Genotyping Techniques; Immunity, Cellular; Lymphocyte Activation; Macaca mulatta; Neutralization Tests; Organophosphonates; RNA-Directed DNA Polymerase; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Treatment Outcome; Viremia; Virus Replication | 2012 |
Double oral administration of emtricitabine/tenofovir prior to virus exposure protects against highly pathogenic simian/human immunodeficiency virus infection in macaques.
Topics: Adenine; Administration, Oral; Animals; Anti-HIV Agents; Antibiotic Prophylaxis; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycytidine; Disease Models, Animal; Emtricitabine; Humans; Macaca; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Tenofovir; Viral Load | 2012 |
Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.
Topics: Adenine; Administration, Topical; Animals; Anti-Infective Agents; Antiviral Agents; Cells, Cultured; Disease Models, Animal; Female; Herpes Genitalis; Interferon-gamma; Interleukin-2; Mice; Mice, Inbred C57BL; Organophosphonates; Tenofovir; Tumor Necrosis Factor-alpha; Vagina; Vaginal Creams, Foams, and Jellies; Virus Shedding | 2012 |
Inefficient vaginal transmission of tenofovir-resistant HIV-1.
Topics: Adenine; Animals; Anti-HIV Agents; Disease Models, Animal; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Mice; Mucous Membrane; Mutation, Missense; Organophosphonates; Suppression, Genetic; Tenofovir; Vagina | 2013 |
The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir.
Topics: Adenine; Amino Acid Substitution; Animals; Antiviral Agents; Computational Biology; Disease Models, Animal; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutant Proteins; Organophosphonates; RNA-Directed DNA Polymerase; Tenofovir | 2013 |
Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus.
Topics: Adenine; Administration, Topical; Animals; Anti-HIV Agents; Disease Models, Animal; Macaca; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2002 |
Development of Vgamma2Vdelta2+ T cell responses during active mycobacterial coinfection of simian immunodeficiency virus-infected macaques requires control of viral infection and immune competence of CD4+ T cells.
Topics: Adenine; Amino Acid Sequence; Animals; Cattle; CD4-Positive T-Lymphocytes; Disease Models, Animal; Drug Therapy, Combination; HIV Protease Inhibitors; Indinavir; Lung; Lymphocyte Count; Macaca mulatta; Macaca nemestrina; Molecular Sequence Data; Mycobacterium bovis; Organophosphonates; Receptors, Antigen, T-Cell, gamma-delta; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Tuberculosis, Bovine | 2004 |
The central nervous system is a viral reservoir in simian immunodeficiency virus--infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy.
Topics: Adenine; Animals; Anti-HIV Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Brain; Disease Models, Animal; DNA, Viral; Drug Therapy, Combination; Histocompatibility Antigens Class II; Injections, Subcutaneous; Macaca nemestrina; Organophosphonates; Polymerase Chain Reaction; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Zalcitabine | 2005 |
Chemoprophylaxis of HIV infection: moving forward with caution.
Topics: Adenine; Animals; Antiviral Agents; Chemoprevention; Disease Models, Animal; HIV Infections; HIV-1; Humans; Macaca mulatta; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2006 |
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges.
Topics: Adenine; Animals; Anti-HIV Agents; Chemoprevention; Disease Models, Animal; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Macaca mulatta; Male; Organophosphonates; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2006 |
A rapid and sensitive real-time PCR assay for the K65R drug resistance mutation in SIV reverse transcriptase.
Topics: Adenine; Animals; Disease Models, Animal; Drug Resistance, Viral; Macaca; Microbial Sensitivity Tests; Organophosphonates; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sensitivity and Specificity; Simian Immunodeficiency Virus; Tenofovir | 2006 |
Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.
Topics: Adenine; Amino Acid Substitution; Animals; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Lymphocyte Depletion; Macaca; Mutation, Missense; Organophosphonates; RNA, Viral; Selection, Genetic; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Viral Load; Viremia | 2007 |
Simian immunodeficiency virus infection induces severe loss of intestinal central memory T cells which impairs CD4+ T-cell restoration during antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Models, Animal; DNA, Viral; Emtricitabine; Flow Cytometry; Immunologic Memory; Lymphoid Tissue; Macaca mulatta; Organophosphonates; Polymerase Chain Reaction; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocyte Subsets; Tenofovir; Viral Load; Virus Replication; Zalcitabine | 2007 |
Direct stringency comparison of two macaque models (single-high vs. repeat-low) for mucosal HIV transmission using an identical anti-HIV chemoprophylaxis intervention.
Topics: Adenine; Administration, Rectal; Animals; Anti-HIV Agents; Antibodies, Viral; Chemoprevention; Disease Models, Animal; Macaca mulatta; Male; Organophosphonates; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2007 |
Development of a novel mouse model to evaluate drug candidates against hepatitis B virus.
Topics: Adenine; Animals; Antiviral Agents; Cell Line; Disease Models, Animal; Drug Evaluation, Preclinical; Hepatitis B; Hepatitis B virus; Lamivudine; Mice; Mice, Nude; Organophosphonates; Reproducibility of Results; Tenofovir | 2007 |
Can the new humanized mouse model give HIV research a boost.
Topics: Adenine; Administration, Intravaginal; Animals; Deoxycytidine; Disease Models, Animal; Disease Susceptibility; Drug Evaluation, Preclinical; Emtricitabine; Female; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Liver Transplantation; Macaca mulatta; Mice; Mice, Inbred NOD; Mice, Inbred Strains; Mice, SCID; Organophosphonates; Radiation Chimera; Species Specificity; Tenofovir; Thymus Gland; Transplantation, Heterologous | 2008 |
Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Topics: Adenine; Administration, Intravaginal; Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Evaluation, Preclinical; Emtricitabine; Female; Fetal Tissue Transplantation; Genitalia, Female; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Immunity, Mucosal; Liver Transplantation; Mice; Mice, Inbred Strains; Mice, SCID; Organophosphonates; Radiation Chimera; Species Specificity; Tenofovir; Thymus Gland; Transplantation, Heterologous | 2008 |
Lasting effects of transient postinoculation tenofovir [9-R-(2-Phosphonomethoxypropyl)adenine] treatment on SHIV(KU2) infection of rhesus macaques.
Topics: Adenine; Animals; Anti-HIV Agents; CD4 Lymphocyte Count; Cerebrospinal Fluid; Disease Models, Animal; Kinetics; Lymph Nodes; Macaca mulatta; Male; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Viral; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir; Time Factors; Viral Load | 2000 |
Post-exposure chemoprophylaxis (PECP) against SIV infection of macaques as a model for protection from HIV infection.
Topics: Adenine; Animals; Disease Models, Animal; DNA, Viral; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Macaca fascicularis; Organophosphonates; Organophosphorus Compounds; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Tenofovir | 2000 |
Development of virus-specific immune responses in SHIV(KU)-infected macaques treated with PMPA.
Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; Disease Models, Animal; HIV Antibodies; HIV Infections; HIV-1; Humans; Macaca mulatta; Neutralization Tests; Organophosphonates; Organophosphorus Compounds; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Tenofovir; Virus Replication | 2001 |
Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment.
Topics: Adenine; Animals; Anti-HIV Agents; Apoptosis; CD8-Positive T-Lymphocytes; Disease Models, Animal; Humans; Immunologic Memory; Macaca mulatta; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; T-Lymphocytes, Helper-Inducer; Tenofovir; Viral Load | 2001 |